ABO blood groups have been proposed to influence malaria parasite infection and disease severity in individuals residing in different geographical areas. In Thailand, genetic polymorphisms of blood groups and susceptibility to malaria infection have rarely been investigated. The aim of this study was to assess the genotype frequencies of ABO and Duffy blood groups and susceptibility to malaria infection in two populations residing in malaria-endemic areas of Thailand. 1100 malaria samples and an identical number of samples from healthy subjects were collected from Thai-Malaysian and Thai-Myanmar areas. Genotyping of ABO and Duffy blood groups was performed by sequence specific primer-polymerase chain reaction. The distribution of ABO and Duffy blood groups was similar in malaria-positive and negative subjects. Blood group O was prevalent in both populations followed by blood group B (BO genotype) and A (AO genotype), respectively. In Plasmodium falciparum infections, blood group A frequency was significantly higher in Thai-Malaysian samples (P = 0.042) whereas blood group B frequency was significantly higher in Thai-Myanmar samples (P = 0.022). FY*A/*A frequency was significantly higher in Plasmodium vivax infection (P = 0.036) while FY*A/*B frequency was significantly higher in healthy subjects (P = 0.005). The different ABO blood group frequencies in the two populations may contribute to susceptibility to P. falciparum infection and the high prevalence of FY*A/*A can confer a risk of P. vivax infection. Further research in various ethnic groups is needed to clarify the association between blood groups and pathogenesis of malaria.
Resistance to antimalarial drugs is a serious issue around the world. Widespread Plasmodium vivax and P. falciparum coinfections are commonly found in Thailand. Dihydroartemisinin and piperaquine (DHA-PPQ) have been used as first-line treatments for P. falciparum since 2015, and chloroquine (CQ) and primaquine (PQ) have remained first-line drugs for P. vivax for more than 60 years. Coinfections may lead parasites to evolve with regard to genetics under selective drug pressure. This study is aimed at investigating genes linked to antimalarial resistance in P. vivax before and after introduction of DHA-PPQ as a new drug regimen in Thailand. A total of 400 P. vivax isolates were collected from samples along the Thai-Myanmar and Thai-Malaysian borders before (2009-2015) and after (2016-2019) introduction of DHA-PPQ. Genomic DNA of P. vivax was obtained and subjected to analysis of five drug resistance-associated genes (Pvdhfr, Pvdhps, Pvmdr1, Pvcrt-o, and PvK12) by nested polymerase chain reaction (PCR), restriction fragment length polymorphism (RFLP), and nucleotide sequencing. A high prevalence of Pvdhfr was found in both endemic areas over the period. The quadruple (57I/58R/61M/117T) Pvdhfr haplotype was predominant in both periods in both endemic areas. Although the wild-type haplotype of Pvdhps was predominant in Thai-Malaysian isolates in both periods, a single mutant haplotype (383G) was dominant in Thai-Myanmar isolates during both periods. A low prevalence of the Pvmdr1 976F mutation was found in both periods among Thai-Myanmar isolates. A significant decrease in Pvmdr1 976F was identified in Thai-Malaysian isolates from the second period (p < 0.01). Only one nonsynonymous mutation of Pvcrt-o (193E) and one synonymous mutation of PvK12 (R584) were detected in four isolates (4.7%) and one isolate (0.5%) in the first period among Thai-Myanmar isolates, respectively. Thus, with limited clinical efficacy data, the low prevalence of drug-resistance markers may suggest that there is a low prevalence of P. vivax-resistant strains and that the current drug regimen for P. vivax is still effective for treating this P. vivax parasite population. Continued surveillance of antimalarial drug resistance markers and monitoring of clinical drug efficacy should be conducted for epidemiological and policy implications.